GSK's Chinese drug sales fell 61% in the third quarter

October 24, 2013 source: GlaxoSmithKline, a British pharmaceutical giant of sina finance, reported on Wednesday that earnings per share in the third quarter was higher than expected and revenue was lower than expected Drug sales in China fell 61 percent The company believes it's too early to quantify the impact of bribery surveys in China The company's third quarter revenue grew 1% to £ 6.51 billion The market is expected to be £ 6.64 billion Core earnings per share were 28.9p, higher than market expectations of 27.2p The third quarter dividend was 19 pence The company expects core earnings per share to grow by 3-4% in fy2013, and revenue to grow by about 1% in the whole fiscal year In the third quarter, the Company repurchased £ 1 billion of company shares, and the target size for the whole year is still £ 1-2 billion In the third quarter, sales of drugs and vaccines outside China increased by 3% In the third quarter, sales of drugs and vaccines in China fell by 61% The company's strategic priority is to develop diversified global businesses and develop more valuable products Its shares fell 0.17% to $51.66 in front of the New York Stock Exchange Its shares rose 0.31% to 1606.32p on the London exchange